Pasithea Therapeutics Corp. Common Stock (KTTA)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Pasithea is a clinical-stage biotech with no revenue in any filed period. It lost $16.0 million in FY2023, $13.9 million in FY2024, and $20.4 million in FY2025. In the fiscal Q2 2026 quarter ended 2026-06-30, the net loss was $5.3 million, worse than the $3.7 million loss in fiscal Q2 2025. That is not a durable operating business; it is a research effort funded by outside capital. There is no moat I can identify from these figures. At the 2026-10-13 close of $0.42, FairStock calculates a market cap of $14.2 million and a P/B of 0.28, so the stock trades below book. But trailing free cash flow is -$17.8 million, a FairStock FCF yield of -125.5% of market cap. The company burns more cash in a year than its entire market value. FairStock’s ROE is -65.49% and ROCE is -36.00%. The Piotroski F-Score is 0/9, and the FairStock Score is 32/100. The Altman Z-Score is 3.51, which might suggest solvency on the given inputs, but no D/E is reported, and with only 5 employees the value lies in intellectual property and trial outcomes, not a proven earning stream. The P/E is -0.27, so earnings give no anchor. Peter Lynch category is none—losses in each of the last four years. Graham would ask for asset protection or earning power. Here both depend on future financing and clinical success. I would watch cash burn, dilution, and trial data, not the low P/B alone.

In plain English: Pasithea Therapeutics is a small drug developer working on treatments for nervous system disorders and some cancers, but it has no product revenue yet. The business looks financially weak because it has lost money for years and burns a lot of cash. The share price is low compared with the value of its assets minus debts on its books, but that does not prove it is a bargain because losses can eat up that value.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer